List of Excipients in Branded Drug RHINOCORT ALLERGY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Johnson & Johnson Consumer Inc McNeil Consumer Healthcare Division	RHINOCORT ALLERGY	budesonide	50580-646	ANHYDROUS DEXTROSE
Johnson & Johnson Consumer Inc McNeil Consumer Healthcare Division	RHINOCORT ALLERGY	budesonide	50580-646	CARBOXYMETHYLCELLULOSE SODIUM
Johnson & Johnson Consumer Inc McNeil Consumer Healthcare Division	RHINOCORT ALLERGY	budesonide	50580-646	CELLULOSE, MICROCRYSTALLINE
Johnson & Johnson Consumer Inc McNeil Consumer Healthcare Division	RHINOCORT ALLERGY	budesonide	50580-646	EDETATE DISODIUM
Johnson & Johnson Consumer Inc McNeil Consumer Healthcare Division	RHINOCORT ALLERGY	budesonide	50580-646	HYDROCHLORIC ACID
Johnson & Johnson Consumer Inc McNeil Consumer Healthcare Division	RHINOCORT ALLERGY	budesonide	50580-646	POLYSORBATE 80
Johnson & Johnson Consumer Inc McNeil Consumer Healthcare Division	RHINOCORT ALLERGY	budesonide	50580-646	POTASSIUM SORBATE

Rhinocort Allergy Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Rhinocort Allergy is an aqueous, multidose nasal suspension containing budesonide at 32 micrograms per spray. Its excipient system is commercially important because it controls suspension stability, dose uniformity, preservative performance, sprayability, and consumer tolerability. The formulation is technically reproducible with established excipients, so the strongest commercial opportunities are differentiated delivery systems, preservative-free presentations, improved sensory performance, and lower-cost private-label products rather than exclusivity based on the existing excipient combination.

Rhinocort Allergy’s core formulation uses microcrystalline cellulose and sodium carboxymethylcellulose as the suspension vehicle; dextrose as a tonicity and bulking agent; polysorbate 80 as a wetting agent; disodium edetate as a chelator; potassium sorbate as a preservative; hydrochloric acid for pH adjustment; and purified water as the vehicle. [1]

What excipients are used in Rhinocort Allergy?

The U.S. Drug Facts labeling identifies budesonide as the active ingredient and lists the following inactive ingredients:

Component	Primary formulation function	Commercial relevance
Microcrystalline cellulose	Suspends and structures budesonide particles	Controls sedimentation, redispersion, and spray consistency
Sodium carboxymethylcellulose	Suspending and viscosity-modifying agent	Supports dose uniformity and suspension stability
Dextrose	Tonicity adjustment and formulation bulking	Influences nasal comfort and osmotic balance
Polysorbate 80	Wetting and surfactant agent	Helps disperse hydrophobic budesonide particles
Disodium edetate	Chelating agent	Limits metal-catalyzed degradation and can support preservative performance
Potassium sorbate	Antimicrobial preservative	Enables multidose packaging
Hydrochloric acid	pH adjustment	Helps maintain chemical and microbiological stability
Purified water	Liquid vehicle	Determines viscosity, spray behavior, and microbial-control requirements

The formulation is a structured suspension rather than a simple dissolved solution. Budesonide has limited water solubility, so the product depends on particle size, wetting, viscosity, agitation behavior, and pump performance to deliver a consistent dose.

How does the Rhinocort Allergy formulation work?

The formulation uses a cellulose-based suspending system to keep micronized budesonide particles dispersed during storage and use. The vehicle must be viscous enough to reduce rapid settling but fluid enough to pass through the metering pump and form a reproducible nasal plume.

The main performance attributes are:

1. Uniform budesonide distribution after shaking.
2. Rapid redispersion after normal storage.
3. Consistent delivered volume per actuation.
4. Narrow spray-pattern and plume variability.
5. Limited dripping from the nasal cavity.
6. Acceptable nasal sensation, odor, and aftertaste.
7. Microbiological control through the preservative system and container closure.

The interaction between microcrystalline cellulose and carboxymethylcellulose is central. A change in polymer grade, particle morphology, substitution level, or viscosity profile can affect sedimentation, redispersion, pump force, plume geometry, and delivered-dose uniformity. A substitute excipient may be pharmaceutically acceptable but still fail comparative performance testing.

What is the commercial role of each Rhinocort Allergy excipient?

Cellulose suspension system

Microcrystalline cellulose and sodium carboxymethylcellulose are widely available, established pharmaceutical excipients. Their broad use reduces raw-material supply risk and weakens the prospect of obtaining meaningful composition-of-matter exclusivity around the existing combination.

The commercial value lies in grade selection and process control. Suppliers can differentiate through:

• Narrower particle-size distributions.
• Lower microbial burden.
• Improved batch-to-batch viscosity control.
• Better redispersion after prolonged storage.
• Lower interaction with preservatives or surfactants.
• Improved compatibility with high-speed filling and pump assembly.

A supplier with a validated cellulose system could pursue formulation-platform licensing to generic nasal-spray manufacturers, particularly where the platform reduces development time or improves delivered-dose robustness.

Polysorbate 80

Polysorbate 80 wets hydrophobic budesonide particles and supports dispersion. Its risks include oxidative degradation, peroxide formation, odor changes, and interaction with packaging or other formulation components. These issues create an opportunity for low-peroxide or oxidation-controlled polysorbate grades.

Potential commercial claims include improved storage stability, reduced degradation products, and better particle wetting. Such claims would require comparative stability and performance data. The excipient itself is unlikely to create strong patent protection because polysorbate 80 is an established material with extensive prior art.

Potassium sorbate

Potassium sorbate permits multidose use by controlling microbial growth. Its performance depends on concentration, pH, container-closure integrity, microbial challenge results, and compatibility with the cellulose system.

A preservative-free product could offer a stronger consumer proposition for patients concerned about nasal irritation or preservative exposure. The tradeoff is greater dependence on sterile manufacturing, container-closure performance, device design, or a validated antimicrobial container system. Preservative removal is not a simple substitution because it changes the microbiological control strategy.

Disodium edetate

Disodium edetate can bind trace metals that promote oxidation or destabilize formulation components. It may also improve preservative performance. Its low concentration makes it inexpensive, but removing it can increase sensitivity to raw-material impurities, water quality, and packaging-derived metals.

An excipient supplier could position low-metal or tightly controlled water and polymer systems as a stability-enabling package. The strongest commercial opportunity would be a complete formulation and process platform, rather than disodium edetate alone.

Dextrose and hydrochloric acid

Dextrose helps adjust tonicity and may affect nasal comfort. Hydrochloric acid is used for pH adjustment and is not normally a meaningful source of product differentiation. Commercial value arises from the final pH range, buffer capacity, and interaction with preservative effectiveness rather than from the identity of the acid.

What formulations are protected by Rhinocort Allergy?

The existing Rhinocort Allergy formulation is built from long-established excipients. The composition therefore has limited standalone patent strength unless protected by narrower parameters such as:

• Budesonide particle-size distribution.
• Specific cellulose ratios.
• Defined viscosity ranges.
• Preservative concentration and pH relationships.
• Spray-pattern and delivered-dose specifications.
• Container-pump interaction.
• Manufacturing conditions that produce a particular suspension structure.
• Improved stability under defined temperature and humidity conditions.

The strongest defensible formulation claims would likely focus on a defined performance result tied to measurable composition or process parameters. Broad claims covering budesonide with cellulose, surfactant, preservative, and water would face substantial prior-art exposure.

When does Rhinocort Allergy lose exclusivity?

Budesonide is an established corticosteroid whose basic active-ingredient exclusivity has expired. The key commercial barriers are therefore regulatory approval, device equivalence, formulation performance, brand recognition, and retail distribution.

Rhinocort Allergy is an over-the-counter product, not a biologic. Biosimilar risk is not relevant. Competitive products can enter through an abbreviated or full regulatory pathway depending on the reference product, dosage form, regulatory designation, and applicable FDA requirements.

For an OTC nasal suspension, a competitor must address:

• Active-ingredient identity and strength.
• Delivered dose per spray.
• Particle-size and suspension characteristics.
• Spray content uniformity.
• Plume geometry and spray pattern.
• Priming and repriming performance.
• Microbiological quality.
• Stability in the marketed container.
• Labeling and consumer-use instructions.

The practical loss of exclusivity occurred when budesonide nasal-spray competition became feasible after active-ingredient and primary product protections expired. Current competition is more likely to be controlled by manufacturing economics and retail positioning than by unexpired basic patents.

What is the Orange Book status of Rhinocort Allergy?

Rhinocort Allergy originated from an FDA-approved budesonide nasal-spray product that was subsequently marketed over the counter. The FDA Orange Book is primarily structured around approved prescription drug products and listed patents or exclusivity. OTC status can make the commercial pathway less straightforward than a conventional prescription ANDA strategy.

A competitor must distinguish among:

• A prescription reference product and its approved drug application.
• An OTC switch or OTC-labeled product.
• A monograph-based OTC product.
• An OTC product requiring an approved application.
• A private-label product relying on an approved manufacturer’s regulatory framework.

The FDA-approved labeling identifies Rhinocort Allergy as budesonide nasal spray, 32 micrograms per spray, for intranasal use. [1] The relevant regulatory issue is not only whether a patent is listed, but whether the proposed product can legally rely on an abbreviated pathway and whether the sponsor must establish its own safety, efficacy, and quality package.

Which companies are challenging Rhinocort Allergy commercially?

The relevant competitors include:

• Generic budesonide nasal sprays.
• Fluticasone propionate nasal sprays.
• Fluticasone furoate nasal sprays.
• Triamcinolone acetonide nasal sprays.
• Mometasone furoate nasal sprays.
• Beclomethasone nasal products.
• Store-brand and retailer-exclusive intranasal corticosteroids.

The most direct commercial competition comes from generic and private-label budesonide products. Fluticasone products compete for the same allergic-rhinitis consumer but have different active ingredients, device characteristics, labeling, and perceived brand value.

For a private-label entrant, the major opportunity is a lower-cost product with equivalent dosing and acceptable sensory characteristics. For a branded entrant, the more credible opportunities are preservative-free delivery, improved pump ergonomics, better pediatric usability, or a product positioned around reduced dripping and postnasal taste.

What excipient strategies could create new commercial opportunities?

Preservative-free multidose systems

A preservative-free product could use a one-way valve, sterile container closure, filtered air pathway, or single-dose packaging. The opportunity is strongest where the device prevents microbial ingress without potassium sorbate.

The regulatory burden is higher because the sponsor must demonstrate microbiological control throughout the in-use period. The commercial benefit must justify a more expensive container and filling process.

Low-drip and low-taste formulations

Nasal corticosteroids can generate consumer complaints involving throat drainage, odor, or taste. A formulation with optimized viscosity, droplet-size distribution, and plume geometry could reduce runoff and improve adherence.

Protection would likely require a combination of formulation and device claims. A formulation-only claim may be difficult if the observed benefit results mainly from pump geometry.

Improved suspension redispersion

A product that redistributes rapidly with fewer shakes could reduce underdosing during consumer use. This opportunity is relevant for older adults, children, and patients who use the product intermittently.

Possible technical levers include polymer ratio, particle-size control, wetting-agent concentration, and manufacturing shear. A sponsor could claim a defined redispersion time combined with delivered-dose uniformity after storage.

Pediatric and accessibility-focused packaging

Rhinocort Allergy is used in allergy treatment across age groups. Commercial differentiation could come from:

• Lower-actuation-force pumps.
• Tactile dose counters.
• Improved cap removal.
• Clearer priming instructions.
• Lockout features.
• Packaging designed for one-handed use.

These features may support device patents and trade dress, although they do not create exclusivity over budesonide itself.

Alternative surfactant and antioxidant systems

Replacing or reducing polysorbate 80 could address oxidation or consumer-perception concerns. Candidate approaches include alternative nonionic surfactants, antioxidant systems, or process controls that reduce the need for surfactant.

The regulatory risk is meaningful because the substitute must preserve particle wetting, stability, dose uniformity, and local tolerability. A formulation with fewer excipients may have a stronger consumer message, but it does not necessarily have a lower development burden.

How strong is the patent estate for Rhinocort Allergy?

The patent estate around the existing excipient system is likely weak to moderate from a freedom-to-operate perspective and stronger only for narrow formulation or device inventions.

Protection category	Likely strength	Main competitive issue
Budesonide active ingredient	Low	Long-established active ingredient
Basic aqueous suspension	Low	Extensive prior art
Cellulose-based suspension vehicle	Low	Established excipient technology
Specific polymer ratios and viscosity	Moderate	Requires narrow claim construction
Preservative-free container system	Moderate to strong	Device and microbiology claims may be defensible
Spray pump and plume control	Moderate	Device-specific performance
Method-of-use claims	Low to moderate	Allergy-treatment use is well established
Manufacturing process	Moderate	Protection depends on non-obvious process parameters
Brand and retail position	Commercially important	Not patent exclusivity

The principal barriers for a generic launch are product-development execution, device qualification, stability, microbiological testing, and scale-up. Patent litigation risk is less likely to center on the old excipient identities and more likely to concern narrow device, process, or performance claims.

What generic launch risks exist for Rhinocort Allergy?

A generic or store-brand entrant faces five primary risks:

1. Suspension failure during long-term storage.
2. Delivered-dose variability after inadequate shaking.
3. Pump performance changes caused by viscosity or particle settling.
4. Preservative failure in the final container.
5. Consumer rejection caused by taste, odor, drip, or difficult priming.

The lowest-risk strategy is to reproduce the established excipient architecture using qualified grades and a comparable pump. The higher-value strategy is to redesign the formulation or container, but this increases regulatory and scale-up risk.

A paragraph IV challenge could be relevant if an applicable listed patent remains in force. The economic value of such a challenge would depend on the remaining market size, patent scope, settlement terms, and the challenger’s ability to establish regulatory equivalence. For an OTC budesonide product, the pathway may not mirror a conventional prescription nasal-spray ANDA challenge.

What licensing deals could support an excipient strategy?

Licensing opportunities fall into four categories:

Excipient platform licensing

A polymer-surfactant suspension platform could be licensed to generic manufacturers. The license would be more valuable if it included development data, supplier qualification, and process parameters.

Device licensing

A preservative-free multidose pump or low-drip spray device could support multiple intranasal products. Device licensing can create recurring revenue without requiring ownership of the active ingredient.

Contract development and manufacturing

A contract manufacturer with validated budesonide suspension capability could offer formulation development, filling, pump assembly, stability programs, and regulatory support. This model benefits from scale and customer switching costs.

Retailer private-label partnerships

Retailers may seek lower-cost equivalents with the same active ingredient and familiar dosage. A supplier able to provide both formulation and regulatory support can capture private-label opportunities more efficiently than an excipient-only supplier.

Public disclosures do not provide a standalone revenue figure for Rhinocort Allergy or a reliable product-level allocation of the brand owner’s respiratory consumer-health revenue. The commercial opportunity should therefore be assessed through category volume, retailer placement, price per dose, gross margin, and expected substitution rather than brand revenue alone.

How does Rhinocort Allergy compare with competing nasal corticosteroids?

Product category	Active ingredient	Formulation opportunity	Main commercial advantage
Rhinocort Allergy	Budesonide	Suspension stability, preservative-free device, low-drip plume	Established allergy brand and corticosteroid efficacy
Flonase-type products	Fluticasone propionate or furoate	Sensory improvement and pump design	Large consumer recognition
Nasacort-type products	Triamcinolone acetonide	Taste, spray comfort, and private label	Broad OTC availability
Nasonex-type products	Mometasone furoate	Device and formulation optimization	Strong prescription and OTC familiarity
Store-brand products	Multiple actives	Cost reduction and packaging	Retail price advantage

The active ingredients differ, so direct substitution requires attention to labeling, strength, dosing instructions, and consumer perception. Excipients and device performance remain important because nasal products compete on daily usability as well as pharmacology.

Key Takeaways

• Rhinocort Allergy contains budesonide in a cellulose-structured aqueous suspension.
• Its key excipients are microcrystalline cellulose, sodium carboxymethylcellulose, dextrose, polysorbate 80, disodium edetate, potassium sorbate, hydrochloric acid, and purified water.
• The existing excipient combination is established and unlikely to support broad patent exclusivity.
• The strongest innovation areas are preservative-free multidose packaging, low-drip spray performance, improved redispersion, low-peroxide surfactant systems, and accessible pump design.
• Generic and private-label competition is commercially feasible because budesonide is an established active ingredient.
• Regulatory risk centers on suspension uniformity, pump equivalence, microbiological control, stability, and consumer-use performance.
• Licensing value is highest for integrated formulation-device platforms rather than individual commodity excipients.
• Biosimilar risk does not apply because Rhinocort Allergy is a small-molecule nasal spray, not a biologic.

FAQs

Can potassium sorbate be removed from Rhinocort Allergy?

Yes, but removal would require a new microbiological-control strategy. A preservative-free product would likely need a redesigned container closure, sterile manufacturing controls, or a validated antimicrobial device system.

Is polysorbate 80 essential for budesonide nasal spray?

It is important for wetting and dispersing hydrophobic budesonide particles in the current formulation, but alternative surfactant or process approaches may be possible. Any substitution must preserve suspension stability, dose uniformity, spray performance, and local tolerability.

Can a cellulose excipient supplier patent a Rhinocort Allergy substitute?

A broad patent on cellulose plus budesonide would face substantial prior art. A narrower patent could be possible for a specific polymer ratio, viscosity range, particle-size profile, manufacturing process, or demonstrated spray-performance result.

What is the most attractive preservative-free opportunity in budesonide nasal spray?

A multidose pump that prevents microbial ingress while maintaining low actuation force and consistent plume geometry offers the strongest combination of technical differentiation and commercial value.

Does an OTC switch eliminate all patent and regulatory risk?

No. OTC status reduces dependence on prescription-market exclusivity but does not eliminate device patents, formulation patents, manufacturing claims, regulatory equivalence requirements, labeling obligations, or trade dress protection.

References

1. U.S. Food and Drug Administration. (n.d.). Rhinocort Allergy: Budesonide nasal spray, 32 mcg per spray, Drug Facts and prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2016). Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation. FDA.

3. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

4. U.S. Food and Drug Administration. (2018). Product-specific guidance for budesonide nasal spray. FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/‑solete.